FL118

SKU: orb1905831

Description

FL118 is a novel camptothecin analog that acts as a survivin inhibitor, suppressing cancer stem cell-like properties. It inhibits epithelial-mesenchymal transition, migration, and invasion in breast cancer cells by targeting the Wnt/β-catenin pathway, as demonstrated in in vitro studies.

Research Area

Cell Biology

Key Properties

• CAS Number: 135415-73-5
• MW: 392.36
• Purity: 98.99% (May vary between batches)
• Formula: C₂₁H₁₆N₂O₆
• SMILES: C(C)[C@]1(O)C2=C(C(=O)N3C(=C2)C=4C(C3)=CC=5C(N4)=CC6=C(C5)OCO6)COC1=O
• Target: IAP,Apoptosis,Survivin
• Solubility: DMSO:2 mg/mL (5.1 mM)

Bioactivity

• In Vivo:
  FL118 (5 and 10 mg/kg; p.o.; once a week; 20 days; female BALB/c nude mice) dose-dependently suppressed ES-2 tumor growth by upregulating CYGB expression. Additionally, FL118 (0-1.5 mg/kg; i.p.; once every other day; five times) effectively eliminated human colon and head-and-neck tumors resistant to irinotecan or topotecan. FL118 (1.5 mg/kg; i.v.; once) also demonstrated favorable pharmacokinetic profiles.
  Read more...
• In Vitro:
  FL118 (0-200 nM; 24, 48, and 72 h) suppresses cell proliferation and migration in ES-2 and SK-O-V3 cells, influencing CYGB expression and inhibiting the PI3K/AKT/mTOR pathway, altering vimentin and E-cadherin levels in ovarian cancer cells. FL118 (0-500 nM; 0-72 h) induces dephosphorylation and degradation of DDX5, regulating survivin, McL-1, XIAP, cIAP2, c-Myc, and mKras expression. FL118 (0-1 μM; 24, 48 h) exhibits cytotoxicity against A549, MDA-MB-231, and RM-1 cell lines, enhancing PARP cleavage and triggering apoptosis in A549 cells, primarily arresting them at the G2/M phase.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

10,11-(Methylenedioxy)-20(S)-camptothecin, 10,11-(Methylenedioxy)-20camptothecin, FL 118, FL118, FL-118, Survivin

Compound Identifiers

PubChem CID

72403